Quoin Pharmaceuticals

Quoin Pharmaceuticals has appointed Sally Lawlor as Chief Financial Officer, bringing over 20 years of pharmaceutical finance experience to guide the company through commercialization preparations.

Quoin Pharmaceuticals' QRX003 demonstrates significant symptom reduction in a Netherton Syndrome clinical trial, with an 83% improvement observed in the first subject after 12 weeks.

Quoin Pharmaceuticals is assessing QRX003 in a pediatric patient with Netherton Syndrome (NS), addressing the need for early treatment in this rare genetic disease.

Quoin Pharmaceuticals initiates an investigator-led clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome, a condition with no approved treatments.

Quoin Pharmaceuticals initiates a clinical study in New Zealand for QRX003 targeting Peeling Skin Syndrome, a condition with no approved treatments.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland in Dublin.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome, a rare genetic disease with no approved treatments.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland, marking the first evaluation of the drug in a pediatric patient.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a pediatric patient with Netherton Syndrome in Dublin.